Blog
RSS FeedPosted by Michael Wonder on 16 Jul 2020
Assessing quantitative comparisons of health and social care between countries
15 July 2020 - Cross-national comparisons in health care and social care may offer insight into quality and cost. ...
Posted by Michael Wonder on 12 Jul 2020
Bill Gates calls for COVID-19 meds to go to people who need them, not 'highest bidder'
11 July 2020 - Billionaire philanthropist Bill Gates called for COVID-19 drugs and an eventual vaccine to be made available ...
Posted by Michael Wonder on 08 Jul 2020
So just who do we think qualifies for any COVID-19 vaccine?
9 July 2020 - How should we allocate scarce medical resources? ...
Posted by Michael Wonder on 07 Jul 2020
Remove the disincentives and biosimilars will flourish, policy expert says
7 July 2020 - Patients could save as much as 17% on out-of-pocket costs if they used biosimilars, but many ...
Posted by Michael Wonder on 02 Jul 2020
ICER publishes white paper on alternative policies for drug and vaccine pricing during a pandemic, announces cross-stakeholder discussion series
2 July 2020 - The Institute for Clinical and Economic Review today published a white paper to inform public and policy ...
Posted by Michael Wonder on 29 Jun 2020
Official complaints
29 June 2020 - PHARMAC responds to all enquiries received from health care professionals and the public on our 0800 ...
Posted by Michael Wonder on 28 Jun 2020
Obamacare faces unprecedented test as economy sinks
27 June 2020 - The battles over the health law have played out during a decade of continuous economic growth. How ...
Posted by Michael Wonder on 25 Jun 2020
How orphan drug policy could impede access to COVID-19 treatments
25 June 2020 - The Orphan Drug Act of 1983 was passed to promote the development of rare disease treatments. ...
Posted by Michael Wonder on 23 Jun 2020
Pricing remdesivir: a domestic reference price approach
23 June 2020 - As COVID-19 continues to ravage US communities, the costs in terms of lives and lost wages are ...
Posted by Michael Wonder on 22 Jun 2020
Alternative payment models—victims of their own success?
22 June 2020 - The US health care system requires major changes to make health care more affordable and higher quality. ...
Posted by Michael Wonder on 11 Jun 2020
Rare disease therapy development and access remain top FDA priorities during COVID-19
11 June 2020 - The FDA’s work on behalf of people with rare diseases is more important than ever as these ...
Posted by Michael Wonder on 26 May 2020
Medicines New Zealand consulting on a new generation medicines policy
26 May 2020 - The New Zealand Institute of Economic Research have produced a discussion paper for Medicines New Zealand ...
Posted by Michael Wonder on 20 May 2020
Insurers back plan for private health plans to cover kids up to age 30
20 May 2020 - The Morrison government is considering a proposal to allow young Australians to stay on their parents' ...
Posted by Michael Wonder on 16 Apr 2020
A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials
16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...
Posted by Michael Wonder on 06 Apr 2020
A coronavirus casualty: delay in comprehensive drug pricing legislation
6 April 2020 - As numbers of new cases of coronavirus mount as well as an increasing death toll, the ...